Vaccine Adjuvants Market to Grow with a CAGR of 6.56% through 2028
Rising technological advancements in vaccine technology and
immunology are expected to drive the Global Vaccine Adjuvants Market growth in
the forecast period, 2024-2028.
According to TechSci Research report, “Vaccine
Adjuvants Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Vaccine Adjuvants Market
stood at USD 0.72 billion in 2022 and is anticipated to grow with a CAGR of 6.56%
in the forecast period, 2024-2028. The Global Vaccine Adjuvants Market is
experiencing a significant surge in demand and growth, primarily driven by key
market drivers that underscore the critical role adjuvants play in enhancing
the efficacy of vaccines. As the world continues to grapple with infectious
diseases, emerging pandemics, and the need for widespread immunization, vaccine
adjuvants have become essential components in the development and deployment of
vaccines. The world has witnessed a slew of infectious disease outbreaks in
recent years, from the H1N1 influenza pandemic to the Zika virus epidemic and,
most notably, the COVID-19 pandemic. These events have underscored the
importance of vaccination in preventing and controlling the spread of
infectious diseases. Vaccine adjuvants have emerged as critical tools in the
development of effective vaccines, as they help stimulate a robust immune
response. The ongoing threat of infectious diseases continues to fuel the
demand for vaccine adjuvants.
Advances in immunology have expanded our understanding
of the human immune system and its response to vaccines. This knowledge has
paved the way for the development of adjuvants that can specifically target and
enhance the desired immune response. Adjuvants are no longer just additives;
they are now precision tools that can be tailored to elicit the most effective
immune response against specific pathogens. This progress in immunology has
spurred research and investment in novel adjuvants, driving market growth. Governments
and healthcare organizations worldwide have recognized the importance of
vaccination as a cornerstone of public health. Consequently, vaccination
programs have expanded, covering an ever-widening range of diseases. As vaccination
becomes more widespread, the demand for adjuvants that can improve vaccine
efficacy and durability grows. This trend is especially notable in emerging
economies, where increasing access to vaccines is driving market expansion.
Beyond traditional prophylactic vaccines, therapeutic
vaccines are gaining traction in the treatment of various conditions, including
cancer, allergies, and autoimmune diseases. Vaccine adjuvants play a crucial
role in enhancing the therapeutic effect of these vaccines. As the development
and utilization of therapeutic vaccines continue to rise, so does the demand
for adjuvants, bolstering market growth.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Vaccine Adjuvants Market.”
The Global Vaccine Adjuvants Market is segmented into Product,
Type, Application, Regional Distribution, And Company.
Based on the Product, the Human Vaccine Adjuvants
emerged as the dominant segment in the global market for Global Vaccine
Adjuvants Market in 2022. Human vaccines are a top priority for global
healthcare systems and governments due to their direct impact on public health.
Preventing and controlling infectious diseases in humans is paramount, and
vaccine adjuvants play a crucial role in enhancing the efficacy of these
vaccines. The human vaccine market encompasses a vast and diverse range of
vaccines targeting various infectious diseases. From childhood immunizations to
adult vaccines and those for emerging threats like COVID-19, there is a
continuous demand for adjuvanted human vaccines across all age groups. Human vaccine
adjuvants benefit from substantial research and innovation investments. These
resources are directed toward improving the safety and efficacy of human
vaccines, expanding the range of diseases they can prevent, and reducing side
effects. As a result, there is a constant drive to develop and refine adjuvants
for human use. Regulatory agencies like the U.S. Food and Drug Administration
(FDA) and the European Medicines Agency (EMA) rigorously evaluate and approve
human vaccines and their adjuvants. The stringent regulatory processes for
human vaccines contribute to their safety and effectiveness, further driving
their demand.
Based on the Application, the Commercial Applications
segment emerged as the dominant player in the global market for Global Vaccine
Adjuvants Market in 2022. Commercial applications in the context of human
vaccines have a profound impact on public health. Vaccination programs
targeting infectious diseases like influenza, hepatitis, and human
papillomavirus (HPV) are essential components of global efforts to prevent
illness and save lives. The demand for adjuvants in these programs is
substantial due to their ability to enhance vaccine effectiveness. commercial
applications are associated with large-scale vaccination campaigns that span
across countries and continents. Governments and healthcare organizations
procure significant quantities of adjuvanted vaccines to meet the vaccination
needs of entire populations, including infants, children, adults, and the
elderly.
Commercial applications encompass a diverse portfolio
of vaccines designed to prevent a wide range of infectious diseases. This
diversity includes routine childhood vaccines, seasonal influenza vaccines,
travel vaccines, and specialized vaccines for emerging infectious diseases.
Adjuvanted vaccines are used in many of these categories, leading to a high
demand. The commercial vaccine market benefits from substantial research and
development investments. Pharmaceutical companies continually invest in developing
new vaccines and improving existing ones, including optimizing adjuvants to
enhance vaccine efficacy. This ongoing innovation contributes to the growth of
commercial applications.
North America emerged as the dominant player in the
global Vaccine Adjuvants Market in 2022, holding the largest market share. The
region boasts a robust healthcare infrastructure and a well-established
pharmaceutical industry, making it a hub for vaccine research, development, and
production. North America is home to numerous prominent pharmaceutical
companies and research institutions that actively engage in vaccine adjuvant
research and innovation. Additionally, stringent regulatory standards and rigorous
evaluation processes by agencies like the U.S. Food and Drug Administration
(FDA) and Health Canada ensure the safety and efficacy of vaccines and
adjuvants. This regulatory framework fosters confidence in adjuvanted vaccines,
encouraging their adoption.
Major companies operating in Global Vaccine
Adjuvants Market are:
- Dynavax Technologies
- Croda International
Plc
- Gsk Plc
- Novavax
- Spi Pharma (A
Subsidiary of Associated British Foods Plc)
- Agenus Inc.
- Phibro Animal Health
Corporation
- Aurorium (Formerly
Vertellus)
- Merck Kgaa
- Vaxine Pty Ltd
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global
Vaccine Adjuvants Market is poised for substantial growth in the coming years.
The
increasing emphasis on vaccination as a primary means of disease prevention,
coupled with the expanding global population, is driving heightened demand for
vaccines, including those with adjuvants. Additionally, advancements in vaccine
technology and the development of innovative adjuvants are expanding the scope
of adjuvanted vaccines, addressing previously unmet medical needs. The focus on
pandemic preparedness, exemplified by the rapid development of COVID-19 vaccines
with adjuvants, has underscored the critical role adjuvants play in responding
to emerging infectious diseases. Furthermore, public health awareness and
government initiatives are promoting vaccine uptake, further fueling the growth
of the vaccine adjuvants market” said Mr. Karan Chechi, Research Director with
TechSci Research, a research-based management consulting firm.
“Vaccine Adjuvants Market - Global Industry
Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product (Adjuvant
Emulsions, Pathogen Components, Saponin-Based Adjuvants, Particulate Adjuvants,
Other Adjuvants), By Type (Human Vaccine Adjuvants, Veterinary Vaccine
Adjuvants), By Application (Research Applications, Commercial Applications) By
Region and Competition”, has evaluated the future growth potential of Global
Vaccine Adjuvants Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Vaccine
Adjuvants Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com